Health6 days ago
Kelun’s ADC Trial with Keytruda Achieves Key Survival Milestone
Chinese biopharmaceutical company Kelun Biotech announced that its phase 3 trial of the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT), in combination with Merck‘s Keytruda (pembrolizumab), has met...
